Multicenter, double-blind, randomized, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute heart failure
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Tezosentan (Primary)
- Indications Acute heart failure
- Focus Registrational; Therapeutic Use
- Acronyms VERITAS-2
- Sponsors Actelion Pharmaceuticals
- 04 Sep 2017 Results (n=1257) of post-hoc analysis of VERITAS studies published in the European Journal of Heart Failure.
- 10 Mar 2017 Results of value of endothelin receptor inhibition with tezosentan data from VERITAS studies published in the European Journal of Heart Failure
- 07 Sep 2007 New trial record.